Sofinnova Investments Inc. Raises Holdings in Celcuity, Inc. $CELC

Sofinnova Investments Inc. increased its stake in shares of Celcuity, Inc. (NASDAQ:CELC) by 18.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 299,417 shares of the company’s stock after purchasing an additional 46,042 shares during the period. Celcuity accounts for 1.2% of Sofinnova Investments Inc.’s investment portfolio, making the stock its 27th largest position. Sofinnova Investments Inc.’s holdings in Celcuity were worth $29,864,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in CELC. State Street Corp lifted its holdings in Celcuity by 126.6% during the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after purchasing an additional 914,887 shares in the last quarter. Apis Capital Advisors LLC purchased a new position in shares of Celcuity during the 3rd quarter valued at about $38,334,000. UBS Group AG raised its holdings in shares of Celcuity by 910.1% during the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after buying an additional 769,891 shares in the last quarter. Deerfield Management Company L.P. purchased a new position in shares of Celcuity during the 3rd quarter valued at about $36,236,000. Finally, Soleus Capital Management L.P. increased its stake in Celcuity by 53.4% in the 4th quarter. Soleus Capital Management L.P. now owns 1,808,258 shares of the company’s stock worth $180,356,000 after purchasing an additional 629,398 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on CELC shares. Craig Hallum decreased their price target on Celcuity from $189.00 to $171.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Macquarie Infrastructure set a $160.00 price target on Celcuity in a research report on Thursday, May 28th. Wells Fargo & Company dropped their price target on Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 3rd. Guggenheim reissued a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $157.00 price target on shares of Celcuity in a research note on Friday, May 15th. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Celcuity currently has an average rating of “Moderate Buy” and a consensus price target of $152.09.

Insider Buying and Selling

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the sale, the director directly owned 6,760 shares in the company, valued at $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director owned 65,000 shares in the company, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 37,000 shares of company stock worth $5,111,950. Company insiders own 13.33% of the company’s stock.

Celcuity Stock Performance

NASDAQ CELC opened at $88.24 on Tuesday. The business has a 50-day moving average price of $119.32 and a 200-day moving average price of $111.22. Celcuity, Inc. has a twelve month low of $11.27 and a twelve month high of $151.02. The firm has a market cap of $4.30 billion, a price-to-earnings ratio of -22.63 and a beta of 0.10. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. As a group, equities research analysts predict that Celcuity, Inc. will post -3.69 EPS for the current fiscal year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.